Current treatments target the mitogen-activated protein kinase (MAPK) pathway, a key driver of melanoma growth. However, MAPK ...

The degree of complexity and crossover within MAPK signaling, and also shifts in pathways such as nuclear factor κB signaling, could also explain the modest effect of p38 inhibitors. The p38α ...

My research focuses on developing rational combinations to overcome drug resistance in melanoma, lung and colorectal cancers. In particular, I explore pharmacological targeting and characterization of ...

Mitogen-activated protein kinase (MAPK) and Wnt signaling pathways are critical for melanocyte ... ligustroside on α-MSH-induced B16F10 murine melanoma cells. The cytotoxicity of ligustroside ...

“The SEACRAFT-2 trial is progressing well, and with FDA Fast Track Designation (FTD) granted in NRASm melanoma ... therapies for patients with RAS/MAPK pathway-driven cancers.

MAPK pathway inhibitors are currently utilized for the therapy of malignant metastatic melanoma. They include RAF inhibitors, such as sorafenib and vemurafenib, or MEK inhibitors such as ...

"The SEACRAFT-2 trial is progressing well, and with FDA Fast Track Designation (FTD) granted in NRASm melanoma, this combination has the potential to be first ... and commercializing therapies for ...